Dual CTLA-4/PD-1 Blockade Versus Anti-PD-1 in MSI-H Metastatic Colorectal Cancer: Early Survival Benefit and Exploratory Clinical Predictors
{{output}}
Introduction: Immune checkpoint inhibitors (ICI) are standard for MSI-H/dMMR metastatic colorectal cancer (mCRC). We compared their efficacy and sought subgroups deriving greater benefit from ICI combination. ... ...
